Published in J Eur Acad Dermatol Venereol on August 18, 2016
New insight into the pathogenesis of nail psoriasis and overview of treatment strategies. Drug Des Devel Ther (2017) 0.75
The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care (1992) 144.02
EQ-5D: a measure of health status from the EuroQol Group. Ann Med (2001) 18.69
Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol (1994) 10.17
The PHQ-8 as a measure of current depression in the general population. J Affect Disord (2008) 8.49
Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol (2012) 4.52
Preference-Based EQ-5D index scores for chronic conditions in the United States. Med Decis Making (2006) 3.62
European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol (2009) 3.56
US norms for six generic health-related quality-of-life indexes from the National Health Measurement study. Med Care (2007) 3.56
The Work Limitations Questionnaire. Med Care (2001) 3.31
The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol (2010) 2.90
Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc (2004) 1.95
Psoriasis prevalence among adults in the United States. J Am Acad Dermatol (2014) 1.83
The psychosocial burden of psoriasis. Am J Clin Dermatol (2005) 1.81
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol (2015) 1.74
Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res (2010) 1.60
Risk of depression in women with psoriasis: a cohort study. Br J Dermatol (2015) 1.45
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol (2015) 1.45
The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol (2014) 1.31
Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials. Health Qual Life Outcomes (2003) 1.17
Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. Cell Signal (2014) 1.16
Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial. J Am Acad Dermatol (2010) 1.10
Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. Br J Dermatol (2005) 1.03
Psoriasis: an epidemiological evaluation of disease burden in 590 patients. J Eur Acad Dermatol Venereol (2010) 0.99
Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial. Br J Dermatol (2009) 0.98
Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study. Health Qual Life Outcomes (2013) 0.98
Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology (2015) 0.95
Depression and anxiety in psoriatic disease: prevalence and associated factors. J Rheumatol (2014) 0.90
The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis. J Invest Dermatol (2013) 0.89
Effects of Apremilast on Pruritus and Skin Discomfort/Pain Correlate With Improvements in Quality of Life in Patients With Moderate to Severe Plaque Psoriasis. Acta Derm Venereol (2016) 0.85
Psoriasis and the Risk of Depression in the US Population: National Health and Nutrition Examination Survey 2009-2012. JAMA Dermatol (2016) 0.85
Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial. J Drugs Dermatol (2013) 0.83
Patient-reported Health-related Quality of Life with apremilast for psoriatic arthritis: a phase II, randomized, controlled study. J Rheumatol (2013) 0.82
Pruritus and quality of life in moderate-to-severe plaque psoriasis: post hoc explorative analysis from the PRISTINE study. J Eur Acad Dermatol Venereol (2014) 0.78
Medication and health care service utilization related to depressive symptoms in older adults with psoriasis. J Drugs Dermatol (2004) 0.78
The International Dermatology Outcome Measures Group: formation of patient-centered outcome measures in dermatology. J Am Acad Dermatol (2014) 0.77